PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
6.32%
Net income growth of 6.32% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
-2.20%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-1825.75%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
19.04%
SBC growth of 19.04% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
204.53%
Working capital of 204.53% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
418.06%
AR growth of 418.06% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
2375.00%
Inventory growth of 2375.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
169.71%
AP growth of 169.71% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
177.58%
Growth of 177.58% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-30.49%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
163.13%
CFO growth of 163.13% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-51.23%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
-1765.89%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.73%
We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-17557.64%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-771.10%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-102.24%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
102.24%
Buyback growth of 102.24% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or higher yoy CFO enabling that difference.